Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

Guardado en:
Detalles Bibliográficos
Autor principal: Martyn E. Caplin
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Cost
Cost-effectiveness
Neuroendocrine tumours
[177Lu]Lu-DOTA-TATE
Quality of life
PFS
Medicine
R
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/c5c9e6e44db5416f8a2cf08a4a7f7f69
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c5c9e6e44db5416f8a2cf08a4a7f7f69
record_format dspace
spelling oai:doaj.org-article:c5c9e6e44db5416f8a2cf08a4a7f7f692021-11-12T04:27:41ZCan the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?1359-634910.1016/j.ejcsup.2021.06.001https://doaj.org/article/c5c9e6e44db5416f8a2cf08a4a7f7f692021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S135963492100001Xhttps://doaj.org/toc/1359-6349Martyn E. CaplinElsevierarticleCostCost-effectivenessNeuroendocrine tumours[177Lu]Lu-DOTA-TATEQuality of lifePFSMedicineRNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENEJC Supplements, Vol 16, Iss , Pp 1-4 (2021)
institution DOAJ
collection DOAJ
language EN
topic Cost
Cost-effectiveness
Neuroendocrine tumours
[177Lu]Lu-DOTA-TATE
Quality of life
PFS
Medicine
R
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Cost
Cost-effectiveness
Neuroendocrine tumours
[177Lu]Lu-DOTA-TATE
Quality of life
PFS
Medicine
R
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Martyn E. Caplin
Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
format article
author Martyn E. Caplin
author_facet Martyn E. Caplin
author_sort Martyn E. Caplin
title Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
title_short Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
title_full Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
title_fullStr Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
title_full_unstemmed Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
title_sort can the peptide receptor radionuclide therapy [177lu]lu-dota-tate provide a net benefit for net patients?
publisher Elsevier
publishDate 2021
url https://doaj.org/article/c5c9e6e44db5416f8a2cf08a4a7f7f69
work_keys_str_mv AT martynecaplin canthepeptidereceptorradionuclidetherapy177luludotatateprovideanetbenefitfornetpatients
_version_ 1718431315139756032

Ejemplares similares